Impel NeuroPharma
0
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Show more...
CEO
Michael Hite
Employees
129
Country
United States
ISIN
US45258K1097
Listings
0 Comments
Share your thoughts
FAQ
What is Impel NeuroPharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Impel NeuroPharma stocks are traded under the ticker 84P.STU.
How many employees does Impel NeuroPharma have?▼
As of July 14, 2026, the company has 129 employees.
In which sector is Impel NeuroPharma located?▼
Impel NeuroPharma operates in the Technology sector.
When did Impel NeuroPharma complete a stock split?▼
Impel NeuroPharma has not had any recent stock splits.
Where is Impel NeuroPharma headquartered?▼
Impel NeuroPharma is headquartered in Seattle, United States.